Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure
Clinical Study
- 25 Downloads
- 19 Citations
Summary
Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.
Key words
malignant glioma glioblastoma brain tumors astrocytoma cisplatin chemotherapyPreview
Unable to display preview. Download preview PDF.
References
- 1.Stewart DJ, O'Bryan RM, Al-Sarraf M, Costanzi JJ, Oishi N: Phase II study of cisplatin in recurrent astrocytomas in adults: A Southwest Oncology Group Study. J Neuro-Oncol 1: 145–147, 1983Google Scholar
- 2.Lehane DE, Bryan RN, Horowitz B, DeSantos L, Ehni G, Zubler MA, Moiel R, Rudolph L, Aldama-Leubbert A, Mahoney D, Harper R: Intraarterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. Cancer Drug Del 1: 69–77, 1983Google Scholar
- 3.Green SB, Shapiro WR, Burger PC, Selker RG, Mahaley MS, Mealey J, Robertson JT, Hochberg FH, VanGilder J, Ransohoff J, Young R: Randomized comparison of intraarterial (IA) cisplatin and intravenous (IV) PCNU for the treatment of primary brain tumors (BTCG Study 8420A). Proc Annu Meet Am Soc Clin Oncol 8: A334, 1989Google Scholar
- 4.Shani J, Wolf W: Modalities of cisplatin administration to brain tumors. Cancer Invest 7: 571–579, 1989Google Scholar
- 5.Burger PC, Dubois PJ, Schold Jr SC, Smith Jr KR, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58: 159–169, 1983Google Scholar
- 6.Burger PC, Heinz ER, Shibata T, Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68: 698–704, 1988PubMedGoogle Scholar
- 7.Kupersmith MJ, Frohman LP, Choi IS, Foo SH, Hiesinger E, Berenstein A, Wise A, Carr RE, Ransohoff J: Visual system toxicity following Intra-arterial chemotherapy. Neurology 38: 284–289, 1988Google Scholar
- 8.Miller DF, Bay JW, Lederman RJ, Purvis JD, Rogers LR, Tomsak RL: Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 92: 402–406, 1985Google Scholar
- 9.Newton HB, Page MA, Junck L, Greenberg HS: Intra-arterial cisplatin for the treatment of malignant gliomas. J Neuro-Oncol 7: 39–45, 1989Google Scholar
- 10.Ali-Osman F, Berger MS, Livingston RB, Spence AM: Cross-resistance patterns of human malignant gliomas to chemotherapeutic agents. Proc Amer Assoc Clin Oncol 8: 86, 1989Google Scholar
- 11.Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH: The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634–656, 1948Google Scholar
- 12.Mahaley Jr MS, Hipp SW, Dropcho EJ, Bertsch L, Cush S, Tirey T, Gillispie GY: Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 70: 371–378, 1989Google Scholar
- 13.ehane DE: Intra-arterial cis-platinum in advanced solid tumors. Dev Oncol 26: 111–124, 1984Google Scholar
- 14.Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984Google Scholar
- 15.Feun LG, Lee Y-Y, Yung WKA, Charnsangavej C, Savaraj N, Tang RA, Wallace S: Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. Cancer Drug Del 3: 147–156, 1986Google Scholar
- 16.EORTC Brain Tumor Group: Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. J Neurosurg 55: 27–31, 1981Google Scholar
- 17.Levin VA, Wilson CB, Rubinstein LJ, Bartyzel L, Vestnys P: Adjuvant chemotherapy with BCNU or the combination of CCNU, procarbazine, and vincristine following irradiation and hydroxyurea for glioblastoma multiforme. Proc Annu Meet Am Assoc Cancer Res 21: 474, 1980Google Scholar
- 18.Nelson DF, Schoenfeld D, Weinstein AS, Nelson JS, Wasserman T, Goodman RL, Carabell S: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of a RTOG study. Int J Radiat Oncol Biol Phys 9: 1143–1151, 1983Google Scholar
- 19.Solero CL, Monfardini S, Brambilla C, Vaghi A, Valagussa P, Morello G, Bonadonna G: Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 2: 43–48, 1979Google Scholar
- 20.DeGregorio M, Wilbur B, King O, Wallenberg J, Prewitt S, Phillips J, Wilbur J: Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of two different methods of cisplatin administration. Cancer Treat Rep 70: 1437–1438, 1986Google Scholar
Copyright information
© Kluwer Academic Publishers 1992